ZimVie (NASDAQ:ZIMV – Get Rating) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $1.80-$2.00 for the period, compared to the consensus estimate of $1.96. The company issued revenue guidance of $915.00 million-$930.00 million, compared to the consensus revenue estimate of $923.00 million.
ZimVie Stock Performance
ZIMV stock opened at $8.94 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. The business’s fifty day moving average price is $8.70 and its two-hundred day moving average price is $14.32. ZimVie has a fifty-two week low of $6.67 and a fifty-two week high of $50.40.
ZimVie (NASDAQ:ZIMV – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.22. The firm had revenue of $214.58 million for the quarter, compared to analysts’ expectations of $214.83 million. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. As a group, analysts anticipate that ZimVie will post 1.95 EPS for the current year.
Institutional Inflows and Outflows
ZimVie Company Profile
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.